Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.
Emmanuelle GrasTommaso Francesco AielloMariana ChumbitaAntonio Gallardo-PizarroPatricia Monzó-GalloChristian Teijón-LumbrerasMaria Suárez-LledóLaura MagnanoMontse TusetMaria Ángeles MarcosAlex SorianoCarolina García-VidalPublished in: The Journal of antimicrobial chemotherapy (2024)
The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.